Study Of Advanced Gastrointestinal Malignancies And Other Solid Tumors
NCT ID: NCT00660426
Last Updated: 2013-04-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
30 participants
INTERVENTIONAL
2005-03-31
2008-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
GTI-2040, Oxaliplatin, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer or Other Solid Tumors
NCT00084643
Gemcitabine, Oxaliplatin and Capecitabine in Patients With Advanced Cholangiocarcinoma
NCT00350961
Gemcitabine, Capecitabine, and Oxaliplatin as Second-Line Therapy in Treating Patients With Advanced Colorectal Cancer Previously Treated With Irinotecan
NCT00496704
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
NCT00004242
Oxaliplatin With Gemcitabine in Patients With Carcinoma of the Urothelial Tract
NCT00127595
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dose Level 1 (starting level)
Oxaliplatin 85 mg/m2 IV on days 1 and 15.
Gemcitabine 800 mg/m2 IV on days 1 and 15.
Capecitabine 600 mg/m2 BID orally on days 1-7 and days 15-21 rounded off to the nearest 150 mg or 500 mg tablet.
Each cycle is 28 days.
Oxaliplatin
Gemcitabine
Capecitabine
Dose Level 2
Oxaliplatin 100 mg/m2 IV on days 1 and 15.
Gemcitabine 800 mg/m2 IV on days 1 and 15.
Capecitabine 600 mg/m2 BID orally on days 1-7 and days 15-21 rounded off to the nearest 150 mg or 500 mg tablet.
Each cycle is 28 days.
Oxaliplatin
Gemcitabine
Capecitabine
Dose Level 3
Oxaliplatin 100 mg/m2 IV on days 1 and 15.
Gemcitabine 800 mg/m2 IV on days 1 and 15.
Capecitabine 800 mg/m2 BID orally on days 1-7 and days 15-21 rounded off to the nearest 150 mg or 500 mg tablet.
Each cycle is 28 days.
Oxaliplatin
Gemcitabine
Capecitabine
Dose Level 4
Oxaliplatin 100 mg/m2 IV on days 1 and 15.
Gemcitabine 1000 mg/m2 IV on days 1 and 15.
Capecitabine 800 mg/m2 BID orally on days 1-7 and days 15-21 rounded off to the nearest 150 mg or 500 mg tablet.
Each cycle is 28 days.
Oxaliplatin
Gemcitabine
Capecitabine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oxaliplatin
Gemcitabine
Capecitabine
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Measurable or Evaluable Disease: See RECIST Criteria: www.cancer.gov/dip/RECIST
3. Age: Patients must be 18 years old or older. Because no dosing or toxicity data are currently available on the use of oxaliplatin in patients \<18 years of age, children are excluded from this study, but will be eligible for other pediatric Phase I single-agent trials, when available.
4. Performance Status: NCI CTC 0-2.
5. Life Expectancy: \>=8 weeks.
6. Recovery from Prior Therapy: Patients must have recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study and must be without significant systemic illness (e.g. infection). No chemotherapy or radiotherapy may be given within 3 weeks prior to the start of protocol treatment. Patients must have received \<= 2 prior chemotherapy regimes.
7. Recovery from Intercurrent Illness: Patients must have recovered from uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris or cardiac arrhythmia.
8. Hematological Status: Patients must have adequate bone marrow function which is defined as an absolute neutrophil count \>= 1,500/mm³, platelet count \>= 100,000/mm³ and hemoglobin \>= 9 g/dl.
9. Hepatic Function: Total bilirubin must be \<= institutional limit of normal (ULN). Transaminases (SGOT and/or SGPT) must be \<= 4 x ULN.
10. Neurological Status: Patients must not have active CNS metastases. Patients with Grade 2 or higher peripheral neuropathy are ineligible due to the potential neurological complications of oxaliplatin therapy.
11. Renal Function: Patients must have adequate renal function defined as serum creatinine \<= 2.0 mg/dl or creatinine clearance \>= 60 ml/min/1.73m² for patients with creatinine levels above 2.0 mg/dl.
12. Sexually Active Patients: For all sexually active patients, the use of adequate barrier contraception (hormonal or barrier method of birth control) will be required during therapy, prior to study entry and for the duration of study participation. Non-pregnant status will be determined in all women of childbearing potential. Pregnant and nursing women patients are not eligible.
13. HIV-Positive Patients: Patients receiving anti-retroviral therapy (HAART) for HIV infection are excluded from the study because of possible pharmacokinetic interactions. Appropriate protocols will be offered to patients receiving HAART therapy, when indicated.
14. No known hypersensitivity to oxaliplatin, gemcitabine or capecitabine
15. No pre-existing clinically significant cardiac, hepatic or renal disease.
16. Informed Consent: After being informed of the treatment involved, patients must give written consent. The patient should not have any serious medical or psychiatric illness that would prevent either the giving of informed consent or the receipt of treatment.
17. Inclusion of Women and Minorities: Entry to this study is open to both men and women and to all racial and ethnic groups.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Washington University School of Medicine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Benjamin Tan, M.D.
Role: PRINCIPAL_INVESTIGATOR
Washington University School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Washington University School of Medicine
St Louis, Missouri, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
04-1213
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.